[{"NetIncomeLoss_2_Q2_USD":-14479000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-14479000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-6435000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-810000.0,"OtherAssetsNoncurrent_0_Q2_USD":1000.0,"Liabilities_0_Q2_USD":12314000.0,"RestructuringAndRelatedCostExpectedCostRemaining1_0_Q2_USD":100000.0,"OperatingLeaseLiability_0_Q2_USD":397000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"GeneralAndAdministrativeExpense_2_Q2_USD":5429000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":2706000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":49276843.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":53077348.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":3020000.0,"OperatingLeaseRightOfUseAssetAmortizationExpense_2_Q2_USD":200000.0,"OperatingLeaseRightOfUseAssetAmortizationExpense_1_Q2_USD":100000.0,"InterestPaidNet_2_Q2_USD":145000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q2_USD":3900000.0,"PaymentsForRestructuring_2_Q2_USD":1385000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":2001000.0,"AssetsCurrent_0_Q2_USD":32521000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-131000.0,"RestructuringCharges_2_Q2_USD":208000.0,"RestructuringCharges_1_Q2_USD":100000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":12695000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_1_Q2_USD":0.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_2_Q2_USD":0.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":-6435000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":-14479000.0,"ShortTermInvestments_0_Q2_USD":0.0,"ClassOfWarrantOrRightOutstanding_0_Q2_shares":7535815.0,"ResearchAndDevelopmentExpense_2_Q2_USD":9939000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":3836000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":600000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-2412000.0,"AccountsReceivableNetCurrent_0_Q2_USD":248000.0,"CommonStockValue_0_Q2_USD":531000.0,"IncomeTaxExaminationPenaltiesAndInterestExpense_2_Q2_USD":0.0,"IncomeTaxExaminationPenaltiesAndInterestExpense_1_Q2_USD":0.0,"ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_2_Q2_USD":16000.0,"LongTermNotesPayable_0_Q2_USD":5380000.0,"CommonStockSharesIssued_0_Q2_shares":53077348.0,"RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_2_Q2_position":44.0,"DepreciationDepletionAndAmortization_2_Q2_USD":132000.0,"DepreciationDepletionAndAmortization_1_Q2_USD":100000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":18983000.0,"RealizedInvestmentGainsLosses_1_Q2_USD":0.0,"RealizedInvestmentGainsLosses_2_Q2_USD":0.0,"InterestAndDebtExpense_2_Q2_USD":235000.0,"InterestAndDebtExpense_1_Q2_USD":94000.0,"PaymentsOfStockIssuanceCosts_2_Q2_USD":1193000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":2000000.0,"ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0_Q2_shares":7535815.0,"CashCashEquivalentsAndShortTermInvestments_0_Q2_USD":30600000.0,"ProceedsFromNotesPayable_2_Q2_USD":1726000.0,"DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2_Q2_USD":19000.0,"Assets_0_Q2_USD":33485000.0,"UnrealizedGainLossOnInvestments_2_Q2_USD":0.0,"UnrealizedGainLossOnInvestments_1_Q2_USD":0.0,"RevenueFromContractWithCustomerIncludingAssessedTax_1_Q2_USD":168000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-182651000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":5736000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":140000.0,"CommonStockSharesOutstanding_0_Q2_shares":53077348.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":0.0,"AmortizationOfFinancingCosts_2_Q2_USD":281000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":3435000.0,"ProceedsFromSaleOfPropertyPlantAndEquipment_2_Q2_USD":1000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":623000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-15248000.0,"LiabilitiesCurrent_0_Q2_USD":6723000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_2_Q2_USD":996000.0,"AccountsPayableCurrent_0_Q2_USD":286000.0,"RestructuringReserveAccrualAdjustment1_2_Q2_USD":39000.0,"NonoperatingIncomeExpense_2_Q2_USD":128000.0,"NonoperatingIncomeExpense_1_Q2_USD":33000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":30582000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":1691000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":13000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":85000.0,"AdditionalPaidInCapital_0_Q2_USD":203291000.0,"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0_Q2_USD":1.13,"NumberOfOperatingSegments_2_Q2_segment":1.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":379000.0,"NetIncomeLoss_1_Q2_USD":-6435000.0,"SaleOfStockNumberOfSharesIssuedInTransaction_2_Q2_shares":2557544.0,"RestructuringAndRelatedCostCostIncurredToDate1_0_Q2_USD":2300000.0,"AccruedRentCurrent_0_Q2_USD":0.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":0.0,"ShareBasedCompensation_2_Q2_USD":1287000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":584000.0,"CommonStockCapitalSharesReservedForFutureIssuance_0_Q2_shares":1541083.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":19754000.0,"RepaymentsOfNotesPayable_2_Q2_USD":1333000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.01,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-762000.0,"CommonStockSharesAuthorized_0_Q2_shares":100000000.0,"ImpairmentOfLongLivedAssetsHeldForUse_2_Q2_USD":0.0,"ImpairmentOfLongLivedAssetsHeldForUse_1_Q2_USD":0.0,"OperatingIncomeLoss_2_Q2_USD":-14372000.0,"OperatingIncomeLoss_1_Q2_USD":-6374000.0,"LongTermInvestments_0_Q2_USD":0.0,"NotesPayableCurrent_0_Q2_USD":3417000.0,"RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2_Q2_pure":0.5,"LiabilitiesAndStockholdersEquity_0_Q2_USD":33485000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":686000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":1287000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":3814000.0,"OperatingExpenses_2_Q2_USD":15368000.0,"OperatingExpenses_1_Q2_USD":6542000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.29,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.12,"OtherLiabilitiesNoncurrent_0_Q2_USD":211000.0,"StockholdersEquity_0_Q2_USD":21171000.0,"RestructuringReserve_0_Q2_USD":377000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":105000.0,"Ticker":"VRDN","CIK":"1590750","name":"MIRAGEN THERAPEUTICS, INC.","OfficialName":"Viridian Therapeutics Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"445189274.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200805"}]